非霍奇金淋巴瘤治疗进展NHLShanghai1Zibv.ppt

* The initial staging PET-CT examination for a sixty-eight year-old lady who was confirmed to have extranodal NK lymphoma, nasal type. Maximum intensity projection (MIP) shows the disseminated nature of the disease with extensive involvement of the bone marrow and lymphadenopathy in the thoracic, abdominal and pelvic cavity (a). Axial CT and fused PET-CT images show metabolically active (grade IV SUVmax) lymphadenopathy at the porta hepatis and marrow deposit at L2 vertebra. * 异基因造血干细胞移植治疗非霍奇金淋巴瘤 预处理方案 Cy(120)-TBI(12Gy) 47 CBV 19 Bu(7)-Cy(50)-TBI(12Gy) 2 VP-16(50)-Cy(100)-TBI(12Gy) 2 Cy(120)-ATG (rabbit)(10)-Flu (150) 1 Bu(16)-Cy(120) 1 Mini-BEAM 1 * 异基因造血干细胞移植治疗非霍奇金淋巴瘤 Direct allo (n = 61) Auto-allo (n = 12) p 0.447 * * * * * * * * * * * * * * * * * * PRO131921 binds to surface CD20 receptors on B cells with high affinity and results in depletion of B cells by several mechanisms, including ADCC, CDC, and?apoptosis. PRO131921 has greater binding affinity to CD20 molecules and has increased ADCC activity relative to rituximab (2.1? to 9.6?fold, respectively). PRO131921 has significantly higher activity than rituximab in a CDC activity assay performed on the B-cell CLL cell lines MEC-1 and EHEB, on PBMCs from three B-cell CLL donors, and on B cells isolated from two healthy human donors. In the WIL-2S cell line, PRO131921 has 1.4-fold increased CDC activity relative to rituximab. Administration of PRO131921 to cynomolgus monkeys and transgenic mice expressing human CD20 and CD16 results in a rapid and marked depletion of B?cells in peripheral blood and tissues. In a GLP cynomolgus monkey study, peripheral blood B?cell recovery was observed following clearing of drug from the body. The duration of B?cell depletion in cynomolgus monkeys appears to be related to drug exposure, and higher doses correlate with longer duration of B?cell depletion. Multiple?dose safety studies in cynomolgus monkeys with PRO131921 identified toxicities